Market Overview

UPDATE: Bank of America Initiates Coverage on Myriad Genetics

Share:
Related MYGN
18 Biggest Mid-Day Losers For Wednesday
Worst Performing Industries For November 2, 2016

According to a research report published this morning, Bank of America has initiated Myriad Genetics (NASDAQ: MYGN) with a Neutral rating and $28 PT.

Bank of America said in the report, "We reinstate Myriad Genetics (MYGN), a leading molecular diagnostics company, with a Neutral rating and $28 price objective. While we are positive about Myriad's initiatives to bolster near-to-midterm sales, we have some reservations about Myriad's long-term growth as its flagship product, BRACAnalysis, matures."

Myriad Genetics closed yesterday at $25.75.

Latest Ratings for MYGN

DateFirmActionFromTo
Nov 2016Stephens & Co.DowngradesOverweightEqual-Weight
Oct 2016Ladenburg ThalmannDowngradesNeutralSell
Oct 2016BarclaysMaintainsEqual-weight

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Analyst Ratings

 

Related Articles (MYGN)

View Comments and Join the Discussion!